Bessemer Group Inc. lifted its position in Boston Scientific Corporation (NYSE:BSX) by 209.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,983 shares of the medical equipment provider’s stock after buying an additional 5,402 shares during the period. Bessemer Group Inc.’s holdings in Boston Scientific Corporation were worth $233,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Swiss National Bank raised its position in shares of Boston Scientific Corporation by 2.9% during the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after purchasing an additional 156,800 shares during the period. Wells Fargo & Company MN raised its position in shares of Boston Scientific Corporation by 10.5% during the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after purchasing an additional 867,983 shares during the period. Sit Investment Associates Inc. raised its position in shares of Boston Scientific Corporation by 37.8% during the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after purchasing an additional 38,855 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Boston Scientific Corporation by 35,016.2% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after purchasing an additional 3,033,800 shares during the period. Finally, LS Investment Advisors LLC raised its position in shares of Boston Scientific Corporation by 5.8% during the third quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock worth $1,185,000 after purchasing an additional 2,209 shares during the period. 90.68% of the stock is currently owned by institutional investors.

A number of research analysts have recently weighed in on the company. UBS AG reiterated a “buy” rating and set a $31.00 price target (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. BidaskClub downgraded Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. SunTrust Banks, Inc. set a $34.00 price target on Boston Scientific Corporation and gave the company a “buy” rating in a report on Tuesday, October 31st. Zacks Investment Research downgraded Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Boston Scientific Corporation has an average rating of “Buy” and a consensus price target of $30.77.

In other news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $26.87, for a total value of $416,485.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total value of $282,200.00. Following the completion of the transaction, the executive vice president now directly owns 164,681 shares of the company’s stock, valued at $4,647,297.82. The disclosure for this sale can be found here. In the last ninety days, insiders sold 508,864 shares of company stock valued at $14,581,669. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation (NYSE BSX) opened at $28.26 on Monday. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $38,810.00, a P/E ratio of 23.16, a price-to-earnings-growth ratio of 2.18 and a beta of 0.99. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the consensus estimate of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.27 EPS. equities research analysts expect that Boston Scientific Corporation will post 1.25 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Bessemer Group Inc. Boosts Stake in Boston Scientific Corporation (BSX)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/20/bessemer-group-inc-boosts-stake-in-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.